Michael Rada’s Post

AstraZeneca India continues to advance its mission of transforming the future of healthcare by unlocking the power of science. The company's commitment to innovation is reflected in its strong pipeline progress, reinforcing its position as a key player in the healthcare industry.   Recently, AstraZeneca unveiled its new Bold Ambition during the Global Investor’s Day setting the stage for 2030! Aspiring to be pioneers in science, focused on transform patient outcomes, by 2030, globally we will deliver 20 new medicines, industry leading growth and aim to be carbon negative.   In India, we have recently announced our financial results for FY 2023-24 with 29% growth in revenue, which is one of our strongest years of performance. We owe this our talented, committed and passionate group of employees who go above and beyond in terms of achieving greater milestones every single day to transform the lives of patients. Proud to be part of a company that is unlocking the power of what science can do for people, society and the planet.   Read more here: https://lnkd.in/gtJHuUeK   #ScienceCan #AZProud

clearly a successful merger back in 1999 -

Collaboration for a Healthier Future! AstraZeneca Pharma India Ltd and Mankind Pharma join forces to enhance access to vital asthma medication in India. Together, INDIA is making strides in healthcare. Stay tuned for more updates and photos from this exciting venture on our LinkedIn page! #pharmacollaboration #healthcareinnovation

Collaboration for a Healthier Future! AstraZeneca Pharma India Ltd and Mankind Pharma join forces to enhance access to vital asthma medication in India. Together, INDIA is making strides in healthcare. Stay tuned for more updates and photos from this exciting venture on our LinkedIn page! #pharmacollaboration #healthcareinnovation 

Today marks a significant milestone in our strategic journey, our commitment to achieving industry-leading growth by reaching $80 billion in total revenue by 2030. This ambition is a testament to our commitment to pushing the boundaries of science for people, society, and the planet. Excited about AstraZeneca's bold ambition to deliver $80bn in annual revenue by 2030! 🚀 We’ll see significant growth in our oncology, biopharmaceuticals and rare disease portfolios, launch 20 new medicines before the end of the decade and leverage transformative technologies to drive innovation. As we continue to grow in all therapy areas, we will continue to decouple carbon emissions from our increase in revenue, halving emissions across our value chain by 2030. 🌱 Let’s work together to unlock the power of what science can do for people, society and the planet. #AZN #WhatScienceCanDo

📢 Lowest Rates for Operationalise Early Access Programmed Europe Expiring Soon 📢 Returning for it's third year, this meeting remains the premier European forum dedicated to defining global regulations and sharing real-world case studies for Early Access Programmes. From exploring the potential of harmonized regulatory frameworks to delving into best practices for establishing robust forecasting models for proactive supply planning, and identifying the types of data that are optimal for research and compliance, this summit is essential for those looking to revolutionize their Early Access Programmes in 2024. 📖 Access the full agenda: https://ter.li/f4tmrb Don’t miss out on the chance to gain invaluable insights from esteemed Early Access professionals, such as those from GSK, Roche, AstraZeneca, Boehringer Ingelheim, BeiGene, Gilead Sciences and many more, at the only European industry event dedicated to navigating complex regulatory and operational hurdles to improve global access to life changing therapeutics. This week is your chance to secure the largest discount on your registration, with savings up to £1,100 expiring midnight Friday, July 5! ✅ Secure your discounted pass here: https://ter.li/99pmr9

🔍 What’s stopping pharma companies from running commercial trials in Africa? We agree it's the right and ethical thing to do, yet it isn't happening... No one wants to be the first. eMQT proposes a change! 🌍 Calling all pharma companies committed to diversity in clinical trials. Join us in building Centres of Excellence together! 🌟 Here’s our simple 3-step proposal: 1️⃣ Meet with eMQT to discuss your therapeutic area and patient population focus. 2️⃣ We identify suitable sites and countries in Africa to match your needs. 3️⃣ Collaborate with us to build Centres of Excellence! Let’s lead the way in transforming clinical research.💡🤝 #DiversityInTrials #ClinicalResearch #PharmaInnovation Contact us today to start the journey! 🌟 https://buff.ly/40eOKUb Pfizer Roche AstraZeneca Gilead Sciences Vertex Pharmaceuticals Veramed Takeda GSK Genentech Novartis Moderna Shalom Ijeoma Lloyd MBE Tina Barton Emily Moore Hannah White Nancy Meyerson-Hess

What’s meaningful to my work here at AstraZeneca? Beyond our dedication to advancing healthcare in Vietnam and ensuring equitable access to the latest and most effective treatments over our 30-year presence in the country, it is the meaningful collaboration and mutual trust we nurture with our stakeholders and partners that truly stand out. On September 30, 2024, I had the privilege of meeting with Vice Minister of the Ministry of Health, Mr. Do Xuan Tuyen, to discuss our ongoing and future contributions to Vietnam’s healthcare landscape. During this meeting, we outlined AstraZeneca Vietnam's key activities in: 💡Pharmaceutical Research and Development 💡Technology Transfer Projects aimed at producing advanced drugs locally. 💡Community Investment Programs aimed at creating an equitable and sustainable healthcare system, enhancing Vietnamese patients' access to advanced medications and treatments. We reaffirmed our alignment with Vietnam’s National Strategy for Pharmaceutical Industry Development and the National Program for Domestic Pharmaceutical Production by 2030, with a vision extending to 2045. Our goal is to support Vietnam in becoming a central hub for producing original brand-name drugs in the ASEAN region. Vice Minister Do Xuan Tuyen expressed high appreciation for AstraZeneca’s contributions and support over the years, particularly during the Covid-19 pandemic. He acknowledged our efforts in technology transfer, clinical trials, disease prevention and control, and our commitment to building a sustainable healthcare system. I felt both supported and encouraged after our discussion. With continued collaboration and support from the Ministry of Health, I am confident that we can achieve remarkable outcomes that benefit our people, society, and the planet. Picture below was taken with Vice Minister Do Xuan Tuyen in Hanoi. More information in Vietnamese: https://lnkd.in/gUH-auz3

Are you attending the World Orphan Drug Congress April 23 - 25th in Boston? If you haven't made a decision yet, here are 3 reasons to attend: 1. #1 Networking opportunity in the rare disease and orphan drug space: The event brings together key stakeholders from across the orphan drug ecosystem, including pharmaceutical companies, biotechs, patient advocacy groups, regulatory agencies, and investors. Networking at the event provides attendees with the chance to forge valuable connections, collaborate on projects, and explore potential partnerships that can drive innovation and advance research in orphan drug development. 2. Access to Industry Insights and Expertise: The event features 3-days of insightful and inspiring presentations, keynote sessions, workshops, roundtables, and so much more led by leading experts and thought leaders in the field of rare diseases and orphan drugs. 3. Learning and Education: whether you’re a researcher clinician, industry executive, or policymaker, WODC will enhance your knowledge base, deepen your understanding of rare diseases, and keep you up to date on the latest advances in orphan drug development and patient care. And if you need another reason, I'll be there and I'd love to connect with you! If you are planning to attend, leave me a comment and let's connect!! #raredisease #rarediseases #rareaccessactionproject #WODC #smallbiopharma

Are you attending the World Orphan Drug Congress April 23 - 25th in Boston? If you haven't made a decision yet, here are 3 reasons to attend: 1. #1 Networking opportunity in the rare disease and orphan drug space: The event brings together key stakeholders from across the orphan drug ecosystem, including pharmaceutical companies, biotechs, patient advocacy groups, regulatory agencies, and investors. Networking at the event provides attendees with the chance to forge valuable connections, collaborate on projects, and explore potential partnerships that can drive innovation and advance research in orphan drug development. 2. Access to Industry Insights and Expertise: The event features 3-days of insightful and inspiring presentations, keynote sessions, workshops, roundtables, and so much more led by leading experts and thought leaders in the field of rare diseases and orphan drugs. 3. Learning and Education: whether you’re a researcher clinician, industry executive, or policymaker, WODC will enhance your knowledge base, deepen your understanding of rare diseases, and keep you up to date on the latest advances in orphan drug development and patient care. And if you need another reason, I'll be there and I'd love to connect with you! If you are planning to attend, leave me a comment and let's connect!! #raredisease #rarediseases #rareaccessactionproject #WODC #smallbiopharma